March 21st 2025
EsoBiotec’s proprietary lentiviral platform primarily enables the immune system to attack cancers but could ultimately offer patients cell therapy treatments delivered in minutes rather than several weeks.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
BIO 2024: Impact of Biosecure Act on the Pharma Industry
June 5th 2024Pharmaceutical Technology® spoke with Parviz Shamlou, senior vice-president of Science and Technology, Abzena, about the impact of the Biosecure Act on the bio/pharmaceutical industry, as well as the progress of continuous manufacturing in biopharma.